SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction?

Translated title of the contribution: SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction?

Juan Antonio Requena-Ibáñez, Carlos G. Santos-Gallego, Juan José Badimón

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

The publication of the EMPEROR-Preserved trial and data on the benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure (HF) with ejection fraction (EF) > 40% represent a significant step forward in the treatment of HF with preserved EF. Given these results, in February 2022 the US Food and Drug Administration approved the use of empaglifozin in adults with HF with reduced or preserved EF. However, more detailed analysis of the EMPEROR-Preserved trial led to doubts about the effect of empagliflozin in patients with an EF of > 60% this patient group is widely heterogeneous and, probably, a single phenotype cannot be considered in treatment goals or the clinical approach. Moreover, EF occurs on a continuum and classifications of HF according to arbitrary cut-points in EF do not appear consistent with recent evidence, which points to a gradual shift and considerable overlap in underlying mechanisms, phenotypes and treatment response over the spectrum of EF. Enhanced knowledge of pathophysiological mechanisms is essential to establish new therapeutic targets, interpret the results of clinical trials, and develop targeted and effective therapies.

Translated title of the contributionSGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction?
Original languageEnglish
JournalRevista Espanola de Cardiologia
DOIs
StatePublished - Oct 2022

Keywords

  • Ejection fraction
  • Heart failure
  • SGLT2 inhibitors

Fingerprint

Dive into the research topics of 'SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction?'. Together they form a unique fingerprint.

Cite this